EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	necitumumab Sensitive: C2 – Inclusion Criteria necitumumab Sensitive : C2	necitumumab Sensitive: C2 – Inclusion Criteria necitumumab Sensitive : C2
EGFR overexpression	Squamous Cell Carcinoma of Head and Neck	EGFR overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2
EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3
EGFR overexpression	Colorectal Cancer	EGFR overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	GC-1118A Sensitive: C3 – Early Trials GC-1118A Sensitive : C3	GC-1118A Sensitive: C3 – Early Trials GC-1118A Sensitive : C3
EGFR overexpression	Lung Adenocarcinoma	EGFR overexpression	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR overexpression	Colorectal Cancer	EGFR overexpression	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR overexpression	Hepatocellular Cancer	EGFR overexpression	Hepatocellular Cancer	gefitinib + lenvatinib Sensitive: C3 – Early Trials gefitinib + lenvatinib Sensitive : C3	gefitinib + lenvatinib Sensitive: C3 – Early Trials gefitinib + lenvatinib Sensitive : C3

EGFR overexpression

Associations